Characterizing advance care planning, palliative care utilization, and location of end-of-life for adult allogeneic hematopoietic stem cell transplant recipients.

Authors

null

Stephanie Hoffman

University of Michigan Rogel Cancer Center, Ann Arbor, MI

Stephanie Hoffman , Pavan Reddy , John Martin Magenau , Attaphol Pawarode , Brian Parkin , Sarah Marie Anand , Monalisa Ghosh , John Joseph Maciejewski , Darren Patrick King , Mary Riwes

Organizations

University of Michigan Rogel Cancer Center, Ann Arbor, MI

Research Funding

No funding received
None

Background: The impacts of advance care planning (ACP) on end-of-life (EOL) outcomes in allogeneic hematopoietic stem cell transplant (allo HCT) recipients are not well known. ACP includes advance directive (AD) completion, and palliative care (PC) consultation. Using these two components, we aimed to explore the current state of ACP and its impact on EOL outcomes in allo HCT recipients to provide the groundwork for future prospective studies. Methods: We performed a retrospective study of deceased adult patients who underwent allo HCT between December 2015-December 2019. We summarized patient characteristics, the rate of AD completion, PC consultation, and location of end-of-life (EOL). Univariate and multivariate analyses were performed to evaluate patient characteristics that may be associated with AD completion, PC consultation and assess the impact of these two factors on location of EOL. Results: See Table for summary of patient characteristics. Of the 125 patients included, we found that 66% (n = 82) completed ADs. All patients with ADs completed them prior to undergoing transplant and never modified them. The majority of patients (84%) with an AD expressed the desire to avoid life-sustaining treatment in the event of terminal illness or irreversible coma. PC was consulted for 46% (n = 58) of patients within 6 months prior to time of death (TOD). Regarding location of EOL, 30% of all patients died in the hospital (non-ICU), 20% in the ICU, 38% at home with hospice, and 10% in a hospice facility. Patients with ADs appeared more likely to die outside of the hospital compared to those without (53% vs. 44%, p = 0.4506). By multivariate analysis, there were no significant patient characteristics associated with the presence of an AD or PC consultation. After adjusting for age and comorbidity index, we found that patients with an AD were significantly more likely to die outside of the ICU (OR 3.0, 95% CI 1.2-7.5, p = 0.02), an effect that was further amplified in patients who both had an AD and received PC consultation at any point (n = 30, p = 0.0077). Conclusions: Our findings highlight the importance of ACP for EOL outcomes in the allo HCT population. While the rate of AD completion in our study population is higher than that of prior studies, future prospective studies aimed to improve the rate of ACP are needed.

Patient characteristicsTotal patients (n = 125)
Age (median ± standard deviation, years)60.7 ± 9.8
Female51 (41%)
Non-Hispanic, White113 (90%)
English as preferred language122 (98%)
Comorbidity index (high; intermediate)62%; 27%
Primary disease (acute leukemia; myelodysplastic syndrome; other63%; 22%; 14%
Disease relapse after transplant74 (59%)
Acute GVHD, any grade70 (56%)
Chronic GVHD, any severity26 (21%)

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Track

Hematologic Malignancies

Sub Track

Allogenic Stem Cell Transplantation

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 7034)

DOI

10.1200/JCO.2021.39.15_suppl.7034

Abstract #

7034

Poster Bd #

Online Only

Abstract Disclosures

Similar Abstracts

First Author: Stephanie Hoffman

Abstract

2024 ASCO Quality Care Symposium

Impact of a mortality prediction tool on end-of-life (EOL) quality measures.

First Author: Jody S. Garey

First Author: Rushil Virendra Patel